ReviewCell death & disease2018
Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies.
Review in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process-A systematic review.Cancer medicine · 2020Pooled it
- Role of the MDM2/p53 axis in regulating cisplatin response in tumor cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Dietary Terpenoids in Advancing Biofilm-Mediated Cancer Prevention: Antibiofilm Cascade, Molecular Crosstalk, and Nano-Facilitated Functional Delivery.Cell biochemistry and function · 2026Review
- Cyclic mechanical stretch suppresses intrinsic apoptosis in high metastatic melanoma.Materials today. Bio · 2026Article
- ColoStem, a core oncofetal signature that identifies poor prognosis colorectal tumors.British journal of cancer · 2026Article
- Biocompatible Dipeptide-Based Nanogels Incorporating Cinnamic Acid for Applications in Skin Disorder Therapy.Pharmaceutics · 2026Article
- Nanotechnology in Cutaneous Oncology: The Role of Liposomes in Targeted Melanoma Therapy.Molecules (Basel, Switzerland) · 2026Review
- Farrerol mitigates lipopolysaccharide-induced acute lung injury through dual regulation of oxidative stress and inflammation via Nrf2 pathway.Open life sciences · 2026Article
- A novel prenylflavonoid with efficacy in cancer therapy by targeting ceramide-orchestrated signaling.Frontiers in pharmacology · 2026Article
- Plexin A2 Knockdown Enhances Apoptosis in Chemotherapy Treated Melanoma Cells.Oncology research · 2026Article
- Development of a hybrid micelle--hydrogel system for topical delivery of doxorubicin to skin cancer cells.Iranian journal of basic medical sciences · 2026Article
- Hydroxytyrosol Reprograms the Tumor Microenvironment in 3D Melanoma Models by Suppressing ERBB Family and Kinase Pathways.International journal of molecular sciences · 2025Article
- Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials.Cells · 2024Review
- Characterization of regulated cancer cell death pathways induced by the different modalities of non-thermal plasma treatment.Cell death discovery · 2024Article
- DNA methylation variations of DNA damage response correlate survival and local immune status in melanomas.Immunity, inflammation and disease · 2024Article
- A Combination of Cardamonin and Doxorubicin Selectively Affect Cell Viability of Melanoma Cells: An In Vitro Study.Antioxidants (Basel, Switzerland) · 2024Article
- Using deep learning to decipher the impact of telomerase promoter mutations on the dynamic metastatic morpholome.PLoS computational biology · 2024Article
- A New Approach to Melanoma Treatment: microRNAs.Current topics in medicinal chemistry · 2024Review
- Nanotechnology-Based Drug Delivery Systems in the Transdermal Treatment of Melanoma.Advanced pharmaceutical bulletin · 2023Review
- Methoxylated Cinnamic Esters with Antiproliferative and Antimetastatic Effects on Human Lung Adenocarcinoma Cells.Life (Basel, Switzerland) · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of malignant melanoma has continued to rise during the past decades. However, in the last few years, treatment protocols have significantly been improved thanks to a better understanding of the key oncogenes and signaling pathways involved in its pathogenesis and progression. Anticancer therapy would either kill tumor cells by triggering apoptosis or permanently arrest them in the G1 phase of the cell cycle. Unfortunately, melanoma is often refractory to commonly used anticancer drugs. More recently, however, some new anticancer strategies have been developed that are "external" to cancer cells, for example stimulating the immune system's response or inhibiting angiogenesis. In fact, the increasing knowledge of melanoma pathogenetic mechanisms, in particular the discovery of genetic mutations activating specific oncogenes, stimulated the development of molecularly targeted therapies, a form of treatment in which a drug (chemical or biological) is developed with the goal of exclusively destroying cancer cells by interfering with specific molecules that drive growth and spreading of the tumor. Again, after the initial exciting results associated with targeted therapy, tumor resistance and/or relapse of the melanoma lesion have been observed. Hence, very recently, new therapeutic strategies based on the modulation of the immune system function have been developed. Since cancer cells are known to be capable of evading immune-mediated surveillance, i.e., to block the immune system cell activity, a series of molecular strategies, including monoclonal antibodies, have been developed in order to "release the brakes" on the immune system igniting immune reactivation and hindering metastatic melanoma cell growth. In this review we analyze the various biological strategies underlying conventional chemotherapy as well as the most recently developed targeted therapies and immunotherapies, pointing at the molecular mechanisms of cell injury and death engaged by the different classes of therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.